Adamas Pharmaceuticals (NASDAQ:ADMS) has its Pdufa date for ADS-5102 to treat levodopa-induced dyskinesia in patients with Parkinson’s disease this week on Aug. 24.
Why is this big news?
The company describes ADS-5102 as: "Potential first and only FDA-approved medicine for treatment of levodopa-induced dyskinesia (LID) in people with Parkinson’s".
Looking at the Amantadine page on the FDA drugs.com website shows that it is listed as: "Amantadine is an antiparkinson and antiviral agent. " so that the doctors treating a Parkinsonian patient have no trouble prescribing Amantidine for the Dyskinesia symptoms, they just write the script for "Parkinson's disease".
As you can from the chart below the stock has pulled back from near $20.
It will be interesting to see how the market reacts to the news on the 24th, I see maybe a downside of $3-4 and upside of $8-$10. This is not investment advice, do your own due diligence before buying or selling $ADMS.
If you got any value out of this post make sure to upvote.